November 16, 2016
8:00am PT, 11:00am ET
Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among women. Hundreds of thousands of women die each year worldwide, and it is estimated that one in eight US women will develop invasive breast cancer in her lifetime.
The heterogeneity of breast cancer with its unique subtypes and genetic mutation profiles makes developing biomarkers and targeted therapies especially important. In addition, the current standard-of-care for most breast cancers is an aggressive course of therapy to prevent progression and metastasis. This course of treatment, however, is far from optimal and considerable overtreatment is known to occur. Thus, it is critically important to identify the underlying mechanisms that drive breast cancer progression and to find novel biomarkers for early detection, prognosis, prediction of treatment response, and to better inform patient treatment options.
Long considered to be genomic “junk,” long non-coding RNAs (lncRNAs) have recently gained widespread attention as critical regulators of coding RNA and alternative splicing, and their dysregulation has been associated with tumorigenesis, tumor progression, and metastasis. With only very recent focus, lncRNAs represent a vast source of largely unstudied potential molecular drivers of human cancer, emerging as a new class of promising cancer biomarkers and therapeutic agents.
During this webinar, our speakers will:
- Demonstrate how novel transcriptome profiling arrays can reliably identify lncRNAs and lead to the discovery of novel cancer biomarkers
- Explain the importance of better understanding the role of lncRNAs in breast cancer progression and tumorigenesis
- Answer your questions live during the broadcast!